Where should a London life sciences company locate?

There is no single best London district for a life sciences company. The correct location follows the work: the laboratory specification, the hospital or university relationship that must be used repeatedly, the people who need to reach the site, the space required after the next milestone and the full occupancy cost. A digital-health company can make a sensible office decision. A cell-therapy company is making an infrastructure decision that happens to involve property.

Start by writing a two-year operating brief before viewing space. Define whether the team needs wet or dry laboratory capacity, containment, specialist gases, backup power, goods access, sample storage, clinical access and room to expand. Then compare the Knowledge Quarter, White City, Whitechapel, SC1, Sutton, Paddington and Canary Wharf against those requirements. A prestigious neighbour does not compensate for a laboratory that cannot support the work.

Define the work before choosing the district

A useful property brief separates what must happen on site from what merely benefits from proximity. Bench science may need controlled ventilation, drainage, higher floor loading, reliable power and safe delivery routes. A diagnostics company may need sample handling and quality-controlled storage. A health-software team may need secure offices and regular access to clinicians, but no laboratory at all.

The distinction matters because laboratory space is not interchangeable with fitted office space. The economy chapter of the Draft London Plan 2026 says life sciences development should address power, water, ventilation, floor loading, floor-to-ceiling height, vibration and digital connectivity. Those are operating requirements, not cosmetic specifications.

The team should document five things before searching:

1. The scientific or clinical work that must occur at the site.
2. The equipment, utilities, safety controls and licences that work requires.
3. The named institutions and people the team expects to use at least monthly.
4. The headcount and laboratory footprint at the next two funding or product milestones.
5. The maximum all-in occupancy cost, including fit-out, service charges, rates, utilities and reinstatement obligations.

This brief prevents a common mistake: choosing a cluster first and attempting to make the science fit later.

The Knowledge Quarter rewards repeated research contact

The Knowledge Quarter around King's Cross, Euston and Bloomsbury brings major research, clinical and cultural institutions into a compact part of central London. The practical advantage is repeated access to UCL, University College Hospital, the Francis Crick Institute and other organisations in the area. It can suit research-intensive teams that need academic collaborators, scientific events and national or international rail connections.

That advantage should be tested, not assumed. A founder should name the facility, principal investigator, clinical team or talent pool that makes the location valuable. Being near a university is not the same as having a collaboration agreement, equipment access or rights to use clinical data. The Knowledge Quarter partnership directory is useful for mapping institutions, but membership is not evidence that a private company can use their facilities.

Central access may help recruitment across several rail corridors, yet fitted space and future expansion can be expensive or constrained. A team expecting rapid bench growth should ask what happens when its current room is full. The answer may involve another building, another district or a split team, each of which adds operational friction.

White City combines university links with grow-on space

White City is anchored by Imperial College London's campus and a growing set of innovation buildings. Imperial says its White City and Old Oak locations support university researchers and companies, and its published innovation-space information should be checked for the current offer rather than treated as proof of availability.

The district can fit companies that value close contact with Imperial research, west London talent and a route from incubator-scale space into larger premises. It may also suit teams whose partners or investors regularly travel through Heathrow. The trade-off is that clinical relationships elsewhere in London can still require substantial cross-city travel.

A company should test the specific journey between its proposed site and the hospital, core facility or collaborator it will use. It should also establish whether specialist equipment is shared or dedicated, who maintains it, when it is accessible and whether use creates intellectual-property or publication conditions. These details matter more than an innovation-district label.

Whitechapel, SC1 and Sutton put clinical relationships first

Whitechapel is closely associated with Barts Health and Queen Mary University of London. SC1 covers a south-central health and life sciences network linked to King's Health Partners and major hospitals around London Bridge, Waterloo and Denmark Hill. Sutton's London Cancer Hub is organised around cancer research, treatment and commercial activity associated with the Institute of Cancer Research and the Royal Marsden.

The London Borough of Sutton's London Cancer Hub overview and the SC1 partnership's current programme describe ambitions as well as existing assets. A company must separate facilities that are operating now from sites, buildings or partnerships that remain planned. That distinction belongs in the board paper and the lease decision.

These locations become compelling when a named clinical workflow is central to the business. A medical-device company may need clinician input, theatre observation and a study site. A therapeutics company may value a disease-specific research community. A digital-health business may need an NHS partner for validation. None of those relationships follows automatically from renting nearby space. Governance, research approvals, contracting and evidence remain separate workstreams.

Paddington and Canary Wharf serve different commercial needs

Paddington offers strong rail access, a direct Elizabeth line connection to Heathrow and an emerging life sciences identity. It can work for international teams, commercial leadership and companies whose laboratory needs are modest or met elsewhere. Before committing, a company should establish whether the relevant building is operational, fitted for its use and available on the required date.

Canary Wharf combines transport, large modern buildings and proximity to financial and professional-services firms. Proposed life sciences development may broaden that offer, but proposed floor area is not usable capacity. The Draft London Plan's cluster material identifies Canary Wharf among innovation and life sciences locations. It does not guarantee a particular laboratory, price or delivery date.

Both districts can be sensible for a headquarters, computational team or later-stage business that values investors, advisers and international connections. A bench-heavy early-stage company should assess fitted capacity, scientific neighbours and the logistics of samples, equipment and waste before prioritising corporate access.

Compare actual premises, not cluster narratives

MedCity's London laboratory-space directory is a practical starting point because it describes providers and planned schemes across several clusters. It is not a live guarantee of vacancy, price or readiness. Every shortlisted premise still needs technical, commercial and legal due diligence.

The comparison should include:

• Laboratory type, containment, utilities and equipment access.
• Fit-out responsibility, programme and reinstatement liability.
• Lease flexibility and the right to expand or contract.
• Rent, service charge, business rates, utilities and specialist waste costs.
• Opening hours, goods access, security and emergency procedures.
• Commutes for the roles that are genuinely difficult to recruit.
• Travel to named hospitals, universities, customers and investors.
• Availability of the next size of premises, not only the first suite.

Specialist science property should also be considered alongside London's broader shortage of operational space. Our planned guide to where London can still make and move things examines the land, power, servicing and freight conditions that office-led property discussions often overlook.

Three operating examples lead to different answers

Consider three hypothetical companies. These examples are decision models, not claims about current tenants or prices.

An early-stage therapeutics spinout with a continuing UCL research relationship may favour the Knowledge Quarter if equipment access and scientific contact outweigh space cost. It should still model where the team moves after the next technical milestone.

A diagnostics company working with Imperial researchers and needing a mix of laboratory and office space may find White City operationally stronger, provided the exact premises meet its quality, power and sample-handling requirements.

A clinical software business working across several NHS trusts may not benefit from laboratory rent at all. It could choose an office near the hospital used most often, or a transport-connected commercial base, while investing in information governance and implementation capacity instead.

The same function-led logic applies to frontier technologies more broadly. Our article on turning London quantum research into paying customers separates research proximity from commercial access. A later comparison of Oxford, Cambridge and London for life sciences operations will test when work should sit outside the capital.

Limitations

Laboratory availability, fit-out condition and commercial terms change faster than strategic cluster descriptions. This draft does not rank buildings, quote rents or confirm vacancies. It also cannot establish whether a company will obtain access to a university facility, NHS partner, clinical study or specialist dataset. Those require separate agreements and approvals.

Several London schemes described by public bodies and developers are planned or under development. They must not be presented as operating capacity until delivery and access have been verified. Before publication, an editor should check every cluster name, facility status, transport assumption and institutional relationship with primary sources dated close to publication.